• Responsible for all aspects of the CLIA lab oncology services business, including operation, commercial, customer service, reimbursement and product development. Lead a team of 20 people • Built oncology testing services with next-generation-sequencing technologies. Strong focus in Lung Cancer with multi-algorithm gene expression risk stratification prognosis for early stage lung cancer patients, and multi-marker molecular profiling for therapy selection for late stage lung cancer patients• Launched one gene-expression assay and three next-generation-sequencing cancer panels in three years for routine clinical testing and patient screening for pharma clinical trial enrollment. Strong product portfolio and market presence in Lung Cancer area, both in US and in Asia• Built a strong project pipeline with leading pharmaceutical customers and leading international cancer institutes in US and Asia. Seamless execution to deliver highest quality results and services to customers• Built partnerships with key oncology testing laboratories overseas. Design training programs and standards for best practice oncology NGS testing in key developing countries• Integrated multiple acquisitions into operation. Built a high performance team and scaled up infrastructure

• Led company-wide annual strategic planning and board presentations• Developed strategy and execution plan in key company growth vectors – diagnostics, forensics, and industrial application with molecular technologies• Led acquisitions of 3 small diagnostics companies; launched new cancer diagnostics startup in the company; developed business and operation plan

• Led acquisitions, divestitures, licensing, equity investment, and strategic partnerships